MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

65.58
-1.61
-2.40%
After Hours: 65.58 0 0.00% 16:36 01/24 EST
OPEN
68.10
PREV CLOSE
67.19
HIGH
68.10
LOW
64.30
VOLUME
1.86M
TURNOVER
--
52 WEEK HIGH
102.98
52 WEEK LOW
64.30
MARKET CAP
3.23B
P/E (TTM)
-8.4338
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BPMC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BPMC News

  • The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
  • Benzinga.2d ago
  • Blueprint Medicines prices equity offering at $69
  • seekingalpha.3d ago
  • Blueprint Medicines Prices 4.7M Share Public Offering of Shares of Common Stock @$69/Share
  • Benzinga.3d ago
  • Hearing Leerink Out Defending Blueprint Medicines; Unconfirmed
  • Benzinga.3d ago

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About BPMC

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
More

Webull offers Blueprint Medicines Corp (BPMC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.